Biologics and small molecules in patients with scalp psoriasis: a systematic review

Abstract Background Scalp psoriasis is common in psoriasis patients, difficult to treat and manifests a significant burden on quality of life. Objective Efficacy assessment of biologics and small molecules in scalp psoriasis with reported safety and quality of life. Methods Biological therapies and small molecules licensed for treatment of plaque psoriasis are assessed. Fourteen studies reporting results from RCTs are included. Efficacy assessment is measured through improvement of Psoriasis Scalp Severity Index (PSSI), Scalp Physician Global Assessment (ScPGA) and/or Scalp-Specific Investigator’s Global Assessment (ss-IGA). Results Among biologics measured by PSSI, brodalumab, secukinumab and in a subgroup ixekizumab showed high efficacy in moderate to severe scalp psoriasis. Both brodalumab and ixekizumab demonstrated rapid response within 2 weeks. Guselkumab was superior to adalimumab and ixekizumab was superior to etanercept. Apremilast showed long-term efficacy. Only few studies reported quality of life in treatment of scalp involvement which showed improvement. All treatments demonstrated acceptable safety profile. Conclusion Effective treatment of scalp psoriasis is essential for improving the quality of life of psoriasis patients. Both Biologics and small molecules proved efficacy. This review may help choosing the appropriate treatment in cases where scalp psoriasis is the main complaint. A unified measurement tool for scalp psoriasis severity is needed to facilitate comparisons.

[1]  C. Griffiths,et al.  Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials , 2018, JAMA dermatology.

[2]  M. Gooderham,et al.  Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P) , 2018, The British journal of dermatology.

[3]  J. Prinz.  Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis , 2018, Front. Immunol..

[4]  M. Lebwohl,et al.  Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. , 2018, Journal of drugs in dermatology : JDD.

[5]  R. Petric,et al.  Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  M. Lebwohl,et al.  The effect of secukinumab on moderate‐to‐severe scalp psoriasis: Results of a 24‐week, randomized, double‐blind, placebo‐controlled phase 3b study , 2017, Journal of the American Academy of Dermatology.

[7]  J. Prinz.  Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis. , 2017, The Journal of investigative dermatology.

[8]  M. Lebwohl,et al.  Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) , 2017, The Journal of dermatological treatment.

[9]  A. Kimball,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.

[10]  A. Armstrong,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA , 2017, Journal of the American Academy of Dermatology.

[11]  M. Gooderham,et al.  The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  T. Tsai,et al.  Managing Scalp Psoriasis: An Evidence-Based Review , 2017, American Journal of Clinical Dermatology.

[13]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[14]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[15]  M. Gooderham,et al.  Management of scalp psoriasis: current perspectives , 2016, Psoriasis.

[16]  J. Schmitt,et al.  Topical treatments for scalp psoriasis. , 2016, The Cochrane database of systematic reviews.

[17]  H. Nakagawa,et al.  Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. , 2016, Journal of dermatological science.

[18]  M. Gooderham,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). , 2016, Journal of the American Academy of Dermatology.

[19]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[20]  A. Menter,et al.  Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[22]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[23]  M. Sundaram,et al.  Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  M. Lebwohl,et al.  A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. , 2014, Journal of the American Academy of Dermatology.

[25]  K. Papp,et al.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial , 2012, The Lancet.

[26]  S. Tyring,et al.  Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. , 2012, Journal of the American Academy of Dermatology.

[27]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[28]  J. Saurat,et al.  A phase IIIb, multicentre, randomized, double‐blind, vehicle‐controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study , 2010, The British journal of dermatology.

[29]  M. Lebwohl,et al.  Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2009, Journal of the American Academy of Dermatology.

[30]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[31]  P. C. van de Kerkhof,et al.  Scalp Psoriasis, Clinical Presentations and Therapeutic Management , 1998, Dermatology.